Bronchitis Companies

Dec 2023GlaxoSmithKline Launched their Ventolin Nebuliser EasyChamber™ solution, offering a user-friendly nebulizer system for children and adults with acute bronchitis.Developed next-generation inhaled corticosteroids with longer-acting properties for improving symptom control in chronic bronchitis.

AstraZeneca (AZ) Received FDA approval for their Bevespi Aerosphere™ inhaler, a combination drug for chronic obstructive pulmonary disease (COPD) with potential benefits for some patients with chronic bronchitis.Partnered with research institutions to explore personalized medicine approaches for managing bronchitis based on individual patient characteristics.

Spiroflow GmbH & Co. KG (Germany) Introduced their SpiroSonic® Airway Clearance System, a non-invasive device generating vibrations that may help clear mucus and improve symptoms in acute and chronic bronchitis.Collaborated with pulmonologists to expand clinical use and evaluate the effectiveness of their SpiroSonic® technology.

Boehringer Ingelheim (Germany) Presented positive Phase 3 trial results for their investigational anti-inflammatory drug BI 785372, demonstrating potential to reduce exacerbations in patients with chronic bronchitis.Announced plans for further clinical trials to confirm and expand upon these promising findings.

World Health Organization (WHO) Emphasized the importance of addressing air pollution and respiratory infections as crucial preventive measures for reducing the burden of bronchitis globally.Collaborated with governments and healthcare organizations to promote public education and implement air quality improvement strategies.

List of Bronchitis Key Companies in the Market

• GlaxoSmithKline Pharmaceuticals Limited


• Boehringer Ingelheim


• Reddy's Laboratories Ltd


• Pfizer Inc.


• Sanofi


• Cathay Drug Company Inc.


• Kaiser Permanente Inc.


• AstraZeneca